Project Grant R21DA059665
Award Date
9/30/24
Completion Date
9/29/26
Dollars Obligated
$451K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
New Hampshire, USA
Similar Awards
This Project Grant award of $2,415,940.00, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to develop digital biomarkers and phenotypes for tracking craving patterns in individuals with opioid use disorder (OUD) during medication-based treatment (MOUD). The award will fund a prospective, observational trial of 300 participants initiating MOUD with buprenorphine, methadone or naltrexone. Continuous wearable...
This federal Project Grant award of $157,684, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a study to understand inequities in harm reduction services (HRS) provided to persons with opioid use disorder in hospital settings. The study will use natural language processing (NLP) and electronic health record (EHR) data to characterize providers' recommendations of psychosocial/environmental and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the NIH's Drug Use and Addiction Research Programs (CFDA 93.279), will fund a $751,043 research project at the University of Massachusetts Medical School focused on investigating the cellular and molecular mechanisms underlying the complex co-morbidity of opioid use disorder (OUD), major depressive disorder (MDD), and HIV in the human brain. The project will leverage single-cell sequencing technologies and other...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $304,215 to Carina Medical LLC to develop and validate a novel software platform for decentralized clinical trials (DCTs) in substance use disorder (SUD). The project aims to leverage large language models (LLMs) to automate data collection and improve efficiency and accuracy for SUD DCTs. Key objectives include developing the software...
The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $591,752 Project Grant to Oprems LLC to develop a digital platform for electronic screening to identify the risk of opioid misuse and overdose. The project aims to integrate the tools and processes from Oprems' existing paper-based "ONE (Opioid and Naloxone Education)" program into a tablet-based digital platform. This digital platform will be used to consistently...
The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $1,088,999 Project Grant to The Trustees of Columbia University in the City of New York, effective August 15, 2024 through May 31, 2029. The objective of this project is to develop efficient statistical estimators for analyzing data fusion of multi-study, multi-outcome clinical trials for treating opioid use disorder. The project aims to: 1) create parametric and...
This Project Grant award of $218,900 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to characterize the formation and maintenance of drug-biased beliefs in individuals with opioid use disorder (OUD). The primary objectives are to: 1) quantify domain-specific optimism biases in OUD and assess how these biases are updated as participants engage in daily life; 2) investigate the neural mechanisms underlying...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $798,828 to Dark Matter Therapeutics, Inc. to discover novel small molecule therapeutics for the safe and effective treatment of opioid use disorder (OUD). The funded project will leverage artificial intelligence (AI) to develop an integrated drug discovery platform called M3.AI that combines target-based and phenotype-based methodologies. The goal...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $722,876 to New York University School of Medicine to conduct a study characterizing complex opioid use disorder (OUD) care trajectories and outcomes following acute service utilization. The study aims to: 1) characterize real-world trajectories of OUD treatment in the year following hospital encounters among treatment-naive individuals and...
This Project Grant award of $397,829 from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), supports the development of an AI platform to discover new therapeutics for substance use disorders (SUDs). The key products and services to be delivered include: Creating a set of curated training datasets and machine learning (ML) models to accelerate drug discovery tasks for SUDs. Identifying mechanistic targets related to the...